Number of shares and votes in Calliditas Therapeutics

Rhea-AI Summary

Calliditas Therapeutics has issued 5,908,018 class C-shares as part of its at-the-market program, increasing total shares to 59,106,188 and votes to 53,788,971.8 as of June 30, 2022. The company focuses on developing treatments for orphan indications, particularly renal and hepatic diseases. Its lead product, TARPEYO, has received FDA approval and awaits European Commission approval. Calliditas is also conducting clinical trials for its NOX inhibitor setanaxib in various conditions. The common shares are listed on Nasdaq Stockholm under ticker CALTX and American Depositary Shares under CALT.

Positive

• FDA approval received for TARPEYO, enhancing commercial prospects.
• Ongoing clinical trials for setanaxib could drive future growth.

Negative

• None.

STOCKHOLM, June 30, 2022 /PRNewswire/ -- During June, Calliditas Therapeutics AB (publ) has issued 5,908,018 class C-shares as part of the establishment of the company's at-the-market program. Thus, as of June 30, 2022, the number of shares and votes in the company amounts to 59,106,188 shares and 53,788,971.8 votes.

For further information, please contact:

Mikael Widell 
Investor relations
Tel.: +46703119960
email: mikael.widell@calliditas.com

The information in the press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 10:00 a.m. CEST on June 30, 2022.

About Calliditas

Calliditas Therapeutics is a commercial stage biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product, TARPEYO^TM (budesonide) delayed release capsules, has been approved by the FDA. This drug product is awaiting European Commission (EC) approval following a positive CHMP opinion. Additionally, Calliditas is conducting a Phase 2b/3 trial with its NOX inhibitor product candidate setanaxib in primary biliary cholangitis and is initiating a head and neck cancer Phase 2 trial with setanaxib. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/calliditas-therapeutics/r/number-of-shares-and-votes-in-calliditas-therapeutics,c3593813

The following files are available for download:

https://mb.cision.com/Main/16574/3593813/1598913.pdf

Number of shares and votes June 2022 (Eng)

 

View original content:https://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-calliditas-therapeutics-301578626.html

SOURCE Calliditas Therapeutics

FAQ

What is the recent stock issuance by Calliditas Therapeutics?

Calliditas Therapeutics issued 5,908,018 class C-shares as part of its at-the-market program.

What is the current number of shares and votes for Calliditas as of June 2022?

As of June 30, 2022, Calliditas has 59,106,188 shares and 53,788,971.8 votes.

What is the lead product of Calliditas Therapeutics?

The lead product of Calliditas is TARPEYO, which is approved by the FDA and awaiting European Commission approval.

What clinical trials is Calliditas currently conducting?

Calliditas is conducting a Phase 2b/3 trial for setanaxib in primary biliary cholangitis and a Phase 2 trial for head and neck cancer.

Where are Calliditas Therapeutics' shares listed?

Calliditas' common shares are listed on Nasdaq Stockholm under ticker CALTX and its American Depositary Shares are under ticker CALT.